cjc 1295 ipamorelin typical dose mcg blend cjc-1295 no dac dosage Blend: Ipamorelin CJC- (No DAC) 20MG CJC-1295 Ipamorelin 10mg
Description
Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients
Mammary gland prolactin receptor and prolactin receptor gene expression The mammary gland prolactin receptor was decreased significantly ( p 0.05)
Since IGF-1 is a target of miR-18b, miR-18b suppression by H19 upregulated IGF-1 to increase chemotherapy resistance
Peptide therapy and TRT are commonly used together
